What this trial means for you
This study is recruiting now at 23 US sites. It's studying KAI-9531, Placebo for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * BMI ≥30 kg/m\^2 or BMI ≥27 kg/m\^2 and previously diagnosed with at least 1 of the following: 1. hypertension, 2. dyslipidemia, 3. obstructive sleep apnea, or 4. cardiovascular (CV) disease. * History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months. Exclusion Criteria: * Current diagnosis or history of diabetes mellitus. * Started medications within 3 months prior to Screening that may cause significant weight gain, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, and mood stabilizers. * Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening. * Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer. * Uncontrolled hypertension or unstable cardiovascular disease. * History of chronic or acute pancreatitis. * Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility. * History of suicide attempt. * History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder. * Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening. Note: Additional inclusion/exclusion criteria may apply, per protocol.
Study sites by state
Alabama
- Kailera Clinical Site — Anniston · Recruiting now
- Kailera Clinical Site — Birmingham · Recruiting now
- Kailera Clinical Site — Cullman · Recruiting now
Arizona
- Kailera Clinical Site — Sun City · Recruiting now
California
- Kailera Clinical Site — Escondido · Recruiting now
- Kailera Clinical Site — Toluca Lake · Recruiting now
Colorado
- Kailera Clinical Site — Aurora · Recruiting now
Connecticut
- Kailera Clinical Site — Bridgeport · Recruiting now
Florida
- Kailera Clinical Site — Jupiter · Recruiting now
Georgia
- Kailera Clinical Site — Lilburn · Recruiting now
Illinois
- Kailera Clinical Site — Springfield · Recruiting now
Maryland
- Kailera Clinical Site — Columbia · Recruiting now
Nevada
- Kailera Clinical Site — Las Vegas · Recruiting now
New York
- Kailera Clinical Site — Rochester · Recruiting now
North Carolina
- Kailera Clinical Site — Morehead City · Recruiting now
Oklahoma
- Kailera Clinical Site — Chickasha · Recruiting now
South Carolina
- Kailera Clinical Site — Mauldin · Recruiting now
Tennessee
- Kailera Clinical Site — Chattanooga · Recruiting now
Texas
- Kailera Clinical Site — Amarillo · Recruiting now
- Kailera Clinical Site — DeSoto · Recruiting now
- Kailera Clinical Site — Tomball · Recruiting now
Utah
- Kailera Clinical Site — Salt Lake City · Recruiting now
Virginia
- Kailera Clinical Site — Danville · Recruiting now
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)